<SEC-DOCUMENT>0000105770-16-000053.txt : 20160112
<SEC-HEADER>0000105770-16-000053.hdr.sgml : 20160112
<ACCEPTANCE-DATETIME>20160112090103
ACCESSION NUMBER:		0000105770-16-000053
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160112
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160112
DATE AS OF CHANGE:		20160112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WEST PHARMACEUTICAL SERVICES INC
		CENTRAL INDEX KEY:			0000105770
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED RUBBER PRODUCTS, NEC [3060]
		IRS NUMBER:				231210010
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08036
		FILM NUMBER:		161337722

	BUSINESS ADDRESS:	
		STREET 1:		101 GORDON DR
		STREET 2:		P O BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645
		BUSINESS PHONE:		6105942900

	MAIL ADDRESS:	
		STREET 1:		101 GORDON DRIVE
		STREET 2:		PO BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WEST CO INC
		DATE OF NAME CHANGE:	19990405
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kjan122016.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>8-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFC27F324185331F023123312747110AE"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:4px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of Earliest Event Reported) &#8211; January 12, 2016 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="westlogo01122016.jpg" style="height:101px;width:252px;"></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="33%"></td><td width="4%"></td><td width="27%"></td><td width="4%"></td><td width="32%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pennsylvania</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-8036</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23-1210010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530 Herman O. West Drive, Exton, PA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19341-0645</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">610-594-2900</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or address, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sD413D556E14AF648D33833127480E211"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 12, 2016, West Pharmaceutical Services, Inc. (the "Company") announced a change to its organization and reporting structure that will support the Company in its next phase of growth and development. Beginning in 2016, the Company will no longer operate two separate units for its Packaging and Delivery Systems businesses.&#160;The Company is establishing global Commercial, Operations and Innovation &amp; Technology organizations in order to provide more comprehensive and tailored offerings to its customers across the Company&#8217;s rich portfolio of products and services.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separately, the Company also announced the appointment of Quintin Lai, Ph.D., to Vice President, Corporate Development, Strategy and Investor Relations ("IR"). Dr. Lai will oversee corporate strategy and investor relations for the Company and report directly to Mr. Green.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to joining the Company, Dr. Lai served as Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation, where he was responsible for developing a global strategy for that S&amp;P 500 company, as well as creating an industry-leading IR function.&#160;From 2002-2012, Dr. Lai served as Managing Director and Senior Equity Research analyst of the Life Science Tools and Diagnostic sector at Robert W. Baird &amp; Company.&#160;Dr. Lai also spent eight years as a Senior Research Engineer at Atlantic Richfield (ARCO).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Lai received a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, an MBA from the University of Chicago Booth School of Business and a B.S. in Chemical Engineering from the University of Alabama.&#160;He is also a CFA charterholder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.16239316239316%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="14%"></td><td width="75%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated January 12, 2016.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sA503D5EB680E78FDEC4D331274BF7F7F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.36752136752136%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="51%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William J. Federici</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William J. Federici</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 12, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s171CD4698EB928696D0B331274DE2653"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="13%"></td><td width="87%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated January 12, 2016.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991pressreleasejan122016.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s535AFEA751AADAB13894331273C58874"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="exh991logo01122016.jpg" style="height:42px;width:245px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="35%"></td><td width="35%"></td><td width="30%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Media Inquiries:</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emily Denney</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Communications</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(610) 594-3035</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">emily.denney@westpharma.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Investors:</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Michael A. Anderson</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Vice President and Treasurer</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(610) 594-3345</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">michael.anderson@westpharma.com</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">John Woolford</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Westwicke Partners</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(443) 213-0506</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">West Announces New Organizational Structure</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exton, PA - Jan. 12, 2016 - </font><font style="font-family:inherit;font-size:11pt;">West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced a change to its organization and  reporting structure that will support the Company in its next phase of growth and development. Beginning in 2016, the company will no longer operate two separate units for its Packaging and Delivery System businesses. West is establishing global Commercial, Operations and Innovation &amp; Technology organizations in order to provide more comprehensive and tailored offerings to its customers across the Company&#8217;s rich portfolio of products and services. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;This is an exciting time for West, as we continue to expand our global footprint, grow our integrated drug containment and delivery product offerings, and take steps to optimize our manufacturing network to help our biotech and pharmaceutical customers deliver innovative, new medicines to patients across the globe,&#8221; said Eric M. Green, President and Chief Executive Officer. &#8220;I am confident that this new organizational structure and the team we have in place to lead it will drive our strategy forward and deliver results for West, our customers and our shareholders.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The new global Commercial Team at West will drive growth across three markets: Biologics, Generics and Pharma, and will include marketing, sales and contract manufacturing services, as well as technical customer support for West&#8217;s full portfolio of offerings. Karen Flynn, Senior Vice President and Chief Commercial Officer, who previously held the position of President, Pharmaceutical Packaging Systems, will lead this organization.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A new global Innovation &amp; Technology Team has been established to create the next generation of products from incubation to the commercial stage, across the packaging, containment and delivery product areas. John Paproski, Senior Vice President and Chief Technology Officer, who previously served as President, Pharmaceutical Delivery Systems, will lead this team.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As announced in October, the Company is accelerating efforts throughout its global supply chain to drive operational excellence to improve service, quality and profitability. The global Operations Team will report directly to Mr. Green.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The remainder of West&#8217;s executive leadership team is unchanged:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">William Federici, Senior Vice President and Chief Financial Officer</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annette Favorite, Senior Vice President and Chief Human Resources Officer</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s535AFEA751AADAB13894331273C58874"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">George Miller, Senior Vice President, General Counsel and Corporate Secretary</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">More details on the organization and reporting structure will be provided at the Company&#8217;s Investor Day, planned for March 10, 2016, in New York, NY. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Separately, the Company also announced today the appointment of Quintin Lai, Ph.D., to Vice President, Corporate Development, Strategy and Investor Relations (IR). Dr. Lai will oversee corporate strategy and investor relations for West and report directly to Mr. Green.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to joining West, Dr. Lai served as Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation, where he was responsible for developing a global strategy for that S&amp;P 500 company, as well as creating an industry-leading IR function.&#160;From 2002-2012, Dr. Lai served as Managing Director and Senior Equity Research analyst of the Life Science Tools and Diagnostic sector at Robert W. Baird &amp; Company.&#160;Dr. Lai also spent eight years as a Senior Research Engineer at Atlantic Richfield (ARCO).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dr. Lai received a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, an MBA from the University of Chicago Booth School of Business and a B.S. in Chemical Engineering from the University of Alabama.&#160;He is also a CFA charterholder.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">About West</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world&#8217;s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West&#8217;s 2014 sales of $1.42 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Forward-Looking Statements </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains forward-looking statements within the meaning of the federal securities laws which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as "plans," "create," "grow," "continue to expand," "will drive," or "deliver results" or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect West's good faith beliefs, assumptions and expectations, they are not guarantees of future performance and there can be no assurance that the reorganization described in this release will accomplish the intended results. Furthermore, except as required by law, West disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in periodic reports under the Securities Exchange Act of 1934, as amended, filed by West from time to time with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"># # #</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exh991logo01122016.jpg
<TEXT>
begin 644 exh991logo01122016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M5RX8I;6\9(\R5@K$#( "LQ(521?_ &D_VD_"7[)OP9UCQUXVU(:;H>CQY;:
MT]W*>([>%,CS)G;Y54=3UP 2/P1_;%_X*4Z;^W1\5H_$WQ"^&^J7UGI2R6^A
MZ3!XZELK;2+=R"V%6T<&:0)'YL@/S% !A5 'Q&493/&3NT^1;M6^Y7:_X![V
M,QD:"M?WGL1_M4_'SPS^WU\<KCQM\1OC-K.BR*C6NE:9:?#BXOK70;,L&%O"
M?[00L254R284R,H)  15P?#WP!_9QOW7^T/VE?%$ /4I\)KB''XF]EK%T_\
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MVN?T6#!0?2@X.:^?_P#@FK^VC:_MW?LJ:'XUVPVNN0L^F:]91/N%G?PX$@'
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MDD;>!='*LK!E8?9(^016.<PIT:,U"*UE:]EHN5/3L:824ISCS-[)[^;/!?\
M@NE^W)X^_9'\(?#30O .L6/A&Z^(6K3VE]XFNH1,ND00B'( *L%SY_F,^UF$
M=N^U23E=3_@G6_[4W@SXYWWA_P")7B'PU\7O@[J&D)J.D>/K*X@5I)WVF-(1
M&=TL;#S X8':1&RR%69:D_X+5?M&>#?@I\.?!>C_ !8^$,GQ"^$_BW64M=8U
ML:C]F_X16=2/*FC54,AN"C3&,K)%G:Z;\L%;Y#_X)(>,M'^'_P#P5CU7X?\
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MYH8VH.2^G_Z 05' =C-GG'E"OI#PO^S-_P % +/;]M_:*^%*[3R6\+?;,_\
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M67:!\@1/E#-)X>81R_+\)[-J,JEK+17;[O>W?\#OP\L3B*W-=J-^[MZ'SO\
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MY'EX'!\S]I4O9;)_\.%K:QV<"1PHL<<:A511M50.  .P [5-117Q)[@4444
M- R*Y#Q'\+E\0?$[0?$QO)(I-#BFB6V" K/Y@(R6SD8SVKKP, T@XJHR:=XF
M=2G":Y9K2Z?S3NA8EVQC/:G445)H-\I<Y]>M-^SJ/6I** &&'(I578*=10 T
MQAFH\E:=10%AHB 4CL::8%/K4E% #3$"*:(.?_KU)10%D-\I:/* S_G%.HH"
MQ'Y"@]Z#;CU:I** LAOE#%((0!^&*?10 P0+GO2^4-O?\Z=10%@4;13?*&2?
K6G44 ,$(!S2M'FG44 ,6$*:4Q9IU% #?)!-)Y"FGT4!9#438*=110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>westlogo01122016.jpg
<TEXT>
begin 644 westlogo01122016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !5 -(# 2(  A$! Q$!_\0
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MZYQ?3OM2@I/Y-V_%HZ,%C/J?"%2VCJS<5\[7_!,^'"<"OZ#_ /@W_P#V7O\
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M/^NIK@?@=\)M3_:'^-WA7P78/)-JGC#5[?31*3E@9I 'E)_V5+.3Z U]A_\
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MV-'\.+6[<>&_AI;1JT"-\DVHW$:RRRL.Y2-XXQGI\^/O&O$O^",_PQ?XJ_\
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M$OO@WX>\8>++?X:R_"FTUS6-8T[4-/-_*K37#RH"8Y@JA(5)P"W^L/TKNO\
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M(U7X-:W'X=\)2_VL8T-NEEIL]A>%A(APES)&Z1\9R6SD9'4UXC^SG^TMX/\
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M/]F_U-JI]O+C\P?]=C7X]_\ !5GQ%_PE'_!2+XT76[>$\3SVH/M"J0_^TZ^
MR;&_7>*<353O&G#D7RDK_C<_0,ZP7U'A;#TGI*I/G?S3M^%CQ%O%UZ?!:Z )
M"--6_.I&,?QS&)8@Q^B@@?[QKZ'_ ."07[+H_:P_;Z\$:)=6WVG0M"G/B+6
M5RGV>U*NJ-[/,88_HYKYEK]L_P#@V9_9?_X0?X ^*?BK?V^V^\<WW]F::[J<
MBPM20[*?1YRX/_7!:^@XNS)9?E56K#24O=7K+K\E=_(^>X0RUYCFM*G/6,?>
M?I'I\W9?,^5?^#E;QQ+XC_;^TG2&)\GPYX3M(T7MNFFGE8_B-@_X#7YZ2OY<
M;-UVC-?I!_P<P_!74_"7[9/AWQRT$K:'XOT"*RCN-I\M+JU>0/$3T!\N2-@.
MX+>AK\X'7>A&<9K3A&5-Y/A_9[<J^_K^-R.+XSCG.(]I_-^'3\#][O!?[!'[
M.G[*7_!.'0O'OQ-^%7AG7KWPQX0M=5UZZDL$EOKVX:%'=07909&D?8N2!G R
M*^5Q_P %&?V "/\ DV+51_W K#_Y*KY[_;'_ ."TGQ,_;+_9NTKX8ZII6A:!
MHT M_P"UKC3FE,VMM %,88,=L:;U5RBYRRCD 8KY1\&^#=6^(OB[3=!T'3;S
M6-;UBX6UL;&UC,D]U*QPJ*HZG/X <G %>!E'"V(=.I6S>K-2<F[1J-)1^3MW
M]$?09MQ7156G0RBE!Q44M::;<OFK_P#!/W/_ &!OVH/V29? OCGXU>#/A;'\
M)-'^'0AT[4]?O=(CCD(NBH\J(6[RLW/E!@!GYU]ZV/VB_P#@I?\ L-?M9^ 7
M\-?$'Q=HGB726)>-;G1-1$MHY&/,AE6$/$_^TA!_"O-_VBO^"?&H?LC?\$ ?
M%O@2UC6\\40);^)_$SVPWB:<7<$MP%(^\D,,84'NL.[O7XF[O0Y%>-DO#> S
M:K5QM.M47)-QBU+6R2L[M-ZMMH]G.^)<?E%*E@ZE&F^>"E)..EVW=632T229
M^E^N?\$,O!7[6GP\U'Q[^RK\45\3Z!;7DMF-+\1VTUO^^C5':**Z,:$D!UQO
MCQSR_6OSF\>^!-7^%_CC5_#>OV,NF:YH-Y+87]I*07MIXV*NA()!P0>02#U%
M?5G[!O\ P6=^(/[ 7P)UCP'X=\.^&=<L;Z]EU&QN=1,JR:=/*BJYPA E3*!@
MIP<YYP<#Y1\;>,M4^(WC+5O$.MWDNH:QKEY+J%]=2?>N)Y7+NY[<L3QVK[C)
M:&:4:]6EC)<U)? W;F:\[6_%7N?"YW7RJM0I5<%'EJOXTK\J]+W_  =CMOV,
M='U#7_VP?A39Z47&HS^+]*%N4^\K"[B.1] "?PK]:O\ @Z ^+9\/_LT?#_P5
M'*%E\3^(7U&9 >6AM(2/R\RXC/U6OG__ (-W_P#@GQJWQ#^-5O\ ''Q'ITUM
MX3\)>8GAXSQE1JVH,IC,T8/6*%6?YNAD*@9V-BG_ ,'/7B^ZU/\ ;(\#:(^X
M6>D>$1<P@]#)/=S!R/PAC'X5\UCL11QW%.'H4W?V*;?KV^6GXGTV!P]; <*X
MBO45G6:2]._SU/S7K]R/^#8_X3?\(M^QYXN\72)MF\7^)7BC/=H+2)8U_P#(
MCS5^&]?<_P#P1!_:)^+E[^UQ\._A)X<\;:QIO@"ZU6?5]3TF-8GADABB>>9=
MS(719"BJ0K#);U->YQM@:N*RFI"G)12]YWOM'6VE]=$>%P/CJ6%S:G.I%R<O
M=5N\M/N/Z"&0.I!&0>H]:_++]M/P]X[_ &7OVD-3TWPY;6\_A_5_^)GHXC\-
M6=V(HG;#PY\ACF-P5&3G:5/>OU-48&*\!_X*-_ ;5?C5^S_<7'AJ>_M_%'AA
MSJ5@+2Y:![E0,30Y##[R<C/\2+7\X)ZG])'P=X9_:=_: M%46'A^>9>,;/ %
MO@_BEL/YUWWAO]K/]JV)E-KX&O;@=O\ BB7C!_%0M>/^$?#7QSU%(VTKQ!XE
M16 *X\9Q1#'&.#<CVKT?PS\)/VL;M!]B\5>(D7L'\<VS#\OM#5H[ >HZ+^UO
M^UXY4-\)XKD?]-M$E@)_.<8_*NQT3]IW]K"\"^9\$="?U+W/V<_^/3FO-=#^
M!O[9K8:/QE/&B]Y_$%M,,>_RM7'>,_B'^U#%K!\'P^-8O%$VLQ&V_P")'?V$
M[-O!#(LBA9%8 '<R@;1DYXJ; -^-W[3OQT_:7^,.F>%K3PK'HFH0RMIL>G1Z
M7'>6[3ASYDQGN(F"J !EE.T*F>:^\OV5/V:+;]GKP-''>SVFL>*KY VJZM'9
M0VYF;KY48C1<0J?N@\GDGD\8G[$O[)3_ +-'@02:UJU[K_C#58U.IWMQ=23I
M".HMX=Y.(U/4]6(R>, >WU+8!1112 _-M_\ @V'^"DCEF\:_%(LQR2;VQ))]
M?^/:F2?\&P7P3="/^$T^*0R,<7MCQ_Y+5^D]%?2?ZX9S_P!!$OP_R/FO]3\F
M_P"@>/X_YF1X!\$:?\-/ NC>'=(A^SZ7H-C#IUG%_P \X8HUC1?P517P?\5O
M^#<OX1?&+XI>)?%VJ^,OB7'J7BC5+G5KI(;NS$223RM(RH#;DA06(&23@#DU
M^@]%>9@<WQF#G*IA:CBY;M=3T\=E&#QD(T\334E'9/H?FRW_  ;"?!,J<>-?
MBD#Z_;+'C_R6K[W^ 7P5T7]G+X+>&? OAV*6+1?"NGQ:=:>:0TLBHN#(Y  +
MNV68@#+,>*Z^BM,PSO'XZ*ABZKFEJK]R,OR/ X&3GA*2@WH['!_M%_LS^"?V
MK_AA>^#_ ![H5MK^A7I$GE2DI);2@';-%(N&CD7)PRD'DCD$@_G)\3O^#6WP
MIJFJSS^#_BMXAT6T=B8[35=+BU QCL/-1XB<>ZDU^J]%7EG$&89>G'"57%/I
MHU]S31GF?#^7Y@U+%TE)KKJG]ZLS\D_!W_!K%IT-XC^(?C)J-S;@_/%IN@1P
M.P]GDF<#_ODU]R_L7?\ !+OX/?L)(UWX+\//-XBEC,4VOZK+]KU*1#U57("Q
M*>ZQJH/?-?0]%;9AQ1FF-@Z>)K-Q?162?K9*_P S++N%\KP,_:8:BE+N[M_)
MMNWR(=0T^#5[">UNH(KFUN8VBFAE0/'*C##*RG@@@D$'@@U^<?[1/_!M-\*/
MBAXHN]5\$>)O$'PZ-Y(TK:?'#'J.G0L23B)'*R(O/"^80.@ '%?I%17'EN<8
MW 2<\'4<&][;/U3T9V9EE&#Q\%#&4U-+:^Z]&M3\@+?_ (-7;C[?B7XUQ_9<
M]4\,?O,?0W.*]Y_9O_X-Q?@C\'=:M]3\6WFO_$N\MF#I;ZFR6NG$CH6@BY?Z
M.[*>X-?H-17JXGC/.:\'3G7=GV2C^*29Y.%X,R;#S]I3H*Z[MO\ !MHJZ)H=
MEX:TJWL-.M+:PL;.-8;>VMXEBA@C485$10 J@<  8%?.?_!07_@EC\./^"BM
MOI5SXK?6-&\0Z%$]O8:SI4J).D+'<89%=622/=\P!&02<$9.?I:BO!PF,KX:
MLJ^'DXS75'OXK!4,31="O!2@^CV/RIF_X-9?"#2YC^+_ (J5,]&T>V9L>F=X
MY_"O?_\ @GM_P1*\%_\ !/[XU2^.]/\ %WB+Q3K+:9-ID*WT$$,%NLK(SR*$
M&[=A-O7HQK[7HKV<5Q9FV)I2H5ZS<9:-62O]R/&PO">4X:K&O1HI2CJG=Z?>
MPI& 92" 01T]:6BOG3Z(_)']N']C"P^"?[1>IP+K?AGP_H'B%VU/25OQ<+LC
M=OWD0\N%P DA( SG:4XYK@M*_9L\/7<)D;XP_"NS91G:\U\&_P#285^E/_!1
M[]F:V_:*^ D\RK.-8\*,VJ63V\(FGD15/G0JI90V]!P,CYD6OR_TKPS\/]7B
M@AM_$'C>?4[MTB@MH?#D,AF=N%1<7622<  #FM(O0#3@^!K7&M6NF:)\2_".
MMZA?3+;6MKIMSJ+RW+L<!%46XR2?\3Q7Z-?L ?\ !/[3?V4/#[:SK$=EJ'CS
M4X]MS=1#=%IT9_Y80$@'TW/@%CQT JC_ ,$__P#@GSIG[-ML/%6M;]2\7ZA%
MB'[3"J'1HF7F)55G E.<.X8_W1QG/U&!BI<NP!1114@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $9%?./[/'_  3[\&?"
M#]H+Q?XWA7[==-J3G1[62$+#H:R1I))Y?)W,6D8!B!M7@#J2447 ^CJ*** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
